Robert W. Baird Lowers IQVIA (NYSE:IQV) Price Target to $212.00

IQVIA (NYSE:IQV - Get Free Report) had its price objective decreased by investment analysts at Robert W. Baird from $213.00 to $212.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a "neutral" rating on the medical research company's stock. Robert W. Baird's price target indicates a potential upside of 5.45% from the company's previous close.

IQV has been the topic of several other research reports. The Goldman Sachs Group reduced their price target on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. reduced their price target on IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a report on Tuesday, November 5th. Leerink Partners reiterated an "outperform" rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Morgan Stanley lowered their target price on IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Finally, Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a report on Tuesday, October 8th. Five investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $255.81.

IQVIA Stock Down 1.1 %

IQV stock traded down $2.15 during mid-day trading on Wednesday, reaching $201.05. The company had a trading volume of 1,457,807 shares, compared to its average volume of 1,186,342. IQVIA has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The firm has a fifty day simple moving average of $214.01 and a 200 day simple moving average of $224.77. The company has a market capitalization of $36.49 billion, a price-to-earnings ratio of 26.39, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Institutional Trading of IQVIA

Several large investors have recently made changes to their positions in the company. ORG Partners LLC boosted its holdings in IQVIA by 2,376.2% in the 2nd quarter. ORG Partners LLC now owns 520 shares of the medical research company's stock worth $108,000 after buying an additional 499 shares during the period. Clear Harbor Asset Management LLC lifted its position in IQVIA by 17.9% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 3,919 shares of the medical research company's stock valued at $829,000 after acquiring an additional 596 shares during the period. Sawgrass Asset Management LLC bought a new position in IQVIA during the 2nd quarter valued at approximately $11,874,000. Blue Trust Inc. increased its holdings in shares of IQVIA by 702.9% in the 2nd quarter. Blue Trust Inc. now owns 281 shares of the medical research company's stock worth $59,000 after purchasing an additional 246 shares in the last quarter. Finally, Gradient Investments LLC boosted its holdings in shares of IQVIA by 15.6% during the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company's stock valued at $9,600,000 after acquiring an additional 6,134 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.